Is axitinib the preferred second-line agent for renal cell carcinoma?
Publication
, Journal Article
Hirsch, BR; George, DJ
Published in: Community Oncology
July 1, 2012
Duke Scholars
Published In
Community Oncology
DOI
ISSN
1548-5315
Publication Date
July 1, 2012
Volume
9
Issue
7
Start / End Page
212 / 213
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hirsch, B. R., & George, D. J. (2012). Is axitinib the preferred second-line agent for renal cell carcinoma? Community Oncology, 9(7), 212–213. https://doi.org/10.1016/j.cmonc.2012.07.001
Hirsch, B. R., and D. J. George. “Is axitinib the preferred second-line agent for renal cell carcinoma?” Community Oncology 9, no. 7 (July 1, 2012): 212–13. https://doi.org/10.1016/j.cmonc.2012.07.001.
Hirsch BR, George DJ. Is axitinib the preferred second-line agent for renal cell carcinoma? Community Oncology. 2012 Jul 1;9(7):212–3.
Hirsch, B. R., and D. J. George. “Is axitinib the preferred second-line agent for renal cell carcinoma?” Community Oncology, vol. 9, no. 7, July 2012, pp. 212–13. Scopus, doi:10.1016/j.cmonc.2012.07.001.
Hirsch BR, George DJ. Is axitinib the preferred second-line agent for renal cell carcinoma? Community Oncology. 2012 Jul 1;9(7):212–213.
Published In
Community Oncology
DOI
ISSN
1548-5315
Publication Date
July 1, 2012
Volume
9
Issue
7
Start / End Page
212 / 213
Related Subject Headings
- Oncology & Carcinogenesis